M. Elisa Vink-Börger

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

Jolien Tol, Miriam Koopman, Annemieke Cats et al. · New England Journal of Medicine · 2009 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +16

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

Nikki Knijn, Leonie J. Mekenkamp, Marjolein Klomp et al. · British Journal of Cancer · 2011 · 289 citations · Full text

Medicine, Oncology, Pathology +16

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab

Jolien Tol, Jeroen R. Dijkstra, Marjolein Klomp et al. · European Journal of Cancer · 2010 · 216 citations

Medicine, Oncology, Pharmacology +14

Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype

Judith E. Grolleman, Richarda M. de Voer, Fadwa A. Elsayed et al. · Cancer Cell · 2019 · 175 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +12

High sensitivity of both sequencing and real‐time PCR analysis of <i>KRAS</i> mutations in colorectal cancer tissue

Jolien Tol, Jeroen R. Dijkstra, M. Elisa Vink-Börger et al. · Journal of Cellular and Molecular Medicine · 2009 · 80 citations · Full text

Medicine, Oncology, Pathology +17